Search Close Search
Search Close Search

UMass Chan Medical School has established the Translational Institute for Molecular Therapeutics, ushering in the next phase of gene therapy development to accelerate new treatments for rare genetic diseases.

 

The institute, led by Miguel Sena-Esteves, PhD, leverages UMass Chan Medical School’s extensive experience in researching and developing gene therapies for early-stage clinical trials and includes infrastructure to assist investigators with manufacturing, regulatory matters and investigational new drug-enabling studies needed to conduct first-in-human clinical trials. Importantly, UMass Chan has GMP and GMP-like manufacturing facilities to produce the necessary biologicals needed for proof-of-concept and pilot clinical trials.

miguel-sena-esteves-phd.jpg

 

About Miguel Sena-Esteves, PhD

Miguel Sena-Esteves, PhD, is associate professor of neurology and a member of the Horae Gene Therapy Center. He received his PhD in biomedical sciences from the University of Porto, Portugal, where he started his work in gene therapy.

 

His laboratory at UMass Chan focuses on the development of adeno-associated virus (AAV) based gene therapies for lysosomal storage diseases, Huntington’s disease, ALS, FSHD and brain tumo

 

Meet Dr. Miguel Sena-Esteves

 

Our research

The Translational Institute for Molecular Therapeutics was formed to evaluate therapies for rare diseases, where there are few options for seeking treatment. The institute leverages UMass Chan Medical School’s extensive experience in researching and developing gene therapies for early-stage clinical trials. It is specifically focused on increasing the number of and reducing the costs associated with human gene therapy clinical trials for rare genetic diseases by establishing a pipeline that moves research seamlessly from discovery to clinical trials and regulatory support.

 

Learn more about our research

envelope.png

Interested in learning more?

Click the link below to get in contact with us

 

Contact us

Latest news

Getting Results…
  • Ana Rita Batista, PhD, (left) instructor in neurology, pictured with Miguel Sena-Esteves, PhD, associate professor of neurology and director of the Translational Institute for Molecular Therapeutics..

    UMass Chan researchers achieve gene therapy milestone for potential Cockayne syndrome treatment

    Researchers working with UMass Chan Medical School’s Translational Institute for Molecular Therapeutics announced progress in developing a vector to deliver gene replacement therapy in mice models with Cockayne syndrome, a rare and fatal neurodegenerative disease that largely affects children and young adults.

    Read more
  • Top story: UMass Chan launches Translational Institute for Molecular Therapeutics

    Top Story: UMass Chan launches Translational Institute for Molecular Therapeutics

    Top story: The Translational Institute for Molecular Therapeutics leverages UMass Chan Medical School’s extensive experience in researching and developing gene therapies for early-stage clinical trials. Miguel Sena-Esteves, PhD, is director of the new institute.

    Read more
  • First gene therapy for Tay-Sachs disease successfully given to two children

    First gene therapy for Tay-Sachs disease successfully given to two children

    In a piece written for The Conversation, Miguel Sena-Esteves, PhD, talks about research leading to the first ever gene therapy for Tay-Sachs disease and the launch of the Translational Institute for Molecular Therapeutics at UMass Chan.

    Read more
Page Menu